-
1
المؤلفون: Michela Verzè, Elisa Giovannetti, Alessandro Leonetti, Amir Avan, Roberta Minari, Alessandro Gregori, Mjriam Capula, Filippo Papini, Paola Bordi, Giulia Mazzaschi, Btissame El Hassouni, Marcello Tiseo
المساهمون: Medical oncology laboratory, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Amsterdam Gastroenterology Endocrinology Metabolism
المصدر: Cells, 10(6):1520. MDPI Multidisciplinary Digital Publishing Institute
Leonetti, A, Capula, M, Minari, R, Mazzaschi, G, Gregori, A, el Hassouni, B, Papini, F, Bordi, P, Verzè, M, Avan, A, Tiseo, M & Giovannetti, E 2021, ' Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs ', Cells, vol. 10, no. 6, 1520 . https://doi.org/10.3390/cells10061520Test
Cells
Cells, Vol 10, Iss 1520, p 1520 (2021)
Volume 10
Issue 6مصطلحات موضوعية: Oncology, Circulating mirnas, Male, Lung Neoplasms, medicine.medical_treatment, Drug Resistance, Disease, Targeted therapy, Basal (phylogenetics), EGFR‐mutated NSCLC, Carcinoma, Non-Small-Cell Lung, Medicine, Biology (General), Non-Small-Cell Lung, Tumor, Gefitinib, General Medicine, Middle Aged, targeted therapy, Response to EGFR‐TKI, response to EGFR-TKI, ErbB Receptors, Female, EGFR-mutated NSCLC, Adult, medicine.medical_specialty, QH301-705.5, Antineoplastic Agents, Afatinib, Article, Erlotinib Hydrochloride, Statistical significance, Internal medicine, microRNA, Biomarkers, Tumor, Humans, Circulating MicroRNA, MiRNA, Aged, Drug Resistance, Neoplasm, MicroRNAs, Mutation, Protein Kinase Inhibitors, Retrospective Studies, miRNA, business.industry, Carcinoma, Retrospective cohort study, Fold change, respiratory tract diseases, Neoplasm, business, Biomarkers
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b195378c54aaed1b56ebdc037e6b7173Test
https://research.vumc.nl/en/publications/9f10a1ce-6a0e-421a-b323-08d160a0846fTest -
2
المؤلفون: Yves Mentens, Jose Ferri, Godefridus J. Peters, Elisa Giovannetti, Nele Van Der Steen, Paul Germonpré, M. Ramael, Patrick Pauwels, Leticia G. Leon, David R. Gandara, Christian Rolfo
المساهمون: CCA - Cancer biology and immunology, Medical oncology laboratory, Medical oncology, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism
المصدر: Van Der Steen, N, Mentens, Y, Ramael, M, Leon, L G, Germonpré, P, Ferri, J, Gandara, D R, Giovannetti, E, Peters, G J, Pauwels, P & Rolfo, C 2018, ' Double Trouble : A Case Series on Concomitant Genetic Aberrations in NSCLC ', Clinical Lung Cancer, vol. 19, no. 1, pp. 35-41 . https://doi.org/10.1016/j.cllc.2017.06.010Test
Clinical Lung Cancer, 19(1), 35-41. Elsevier
Clinical lung cancerمصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Viral Oncogene, medicine.disease_cause, Targeted therapy, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Exon, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Genetic Testing, Molecular Targeted Therapy, Epidermal growth factor receptor, Neoplasm Metastasis, Lung cancer, Genetic testing, biology, medicine.diagnostic_test, business.industry, Middle Aged, Proto-Oncogene Proteins c-met, medicine.disease, ErbB Receptors, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Cancer research, biology.protein, Female, Human medicine, KRAS, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::184d2225d523195834ff5aba158882edTest
https://doi.org/10.1016/j.cllc.2017.06.010Test -
3
المساهمون: Surgery, Medical oncology laboratory, CCA - Target Discovery & Preclinial Therapy Development
المصدر: Meijer, L L, Puik, J R, Peters, G J, Kazemier, G & Giovannetti, E 2016, ' hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients ', The Oncologist, vol. 21, no. 12, pp. e4 . https://doi.org/10.1634/theoncologist.2016-0262Test
The Oncologist
The Oncologist, 21(12). AlphaMed Pressمصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Antimetabolites, Antineoplastic, medicine.medical_treatment, Treatment outcome, Equilibrative nucleoside transporter 1, Deoxycytidine, Disease-Free Survival, Cholangiocarcinoma, Equilibrative Nucleoside Transporter 1, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, Letters to the Editor, Aged, Chemotherapy, biology, business.industry, Middle Aged, Gemcitabine, 030104 developmental biology, Bile Duct Neoplasms, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, biology.protein, Biomarker (medicine), Female, business, Adjuvant, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2356f1bce196ea80a75555ea4263dae6Test
https://doi.org/10.1634/theoncologist.2016-0262Test -
4
المساهمون: Medical oncology laboratory, CCA - Innovative therapy
المصدر: Journal of Cancer Research and Clinical Oncology, 141(7), 1189-1194. Springer Verlag
Vasile, E, Tibaldi, C, Leon, G L, D'Incecco, A & Giovannetti, E 2015, ' Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients ', Journal of Cancer Research and Clinical Oncology, vol. 141, no. 7, pp. 1189-1194 . https://doi.org/10.1007/s00432-014-1880-3Testمصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, CYP1B1, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Single-nucleotide polymorphism, Docetaxel, Polymorphism, Single Nucleotide, Biomarkers, Pharmacological, Polymorphism (computer science), Carcinoma, Non-Small-Cell Lung, Internal medicine, Tumor Cells, Cultured, medicine, Carcinoma, Humans, neoplasms, Genetic Association Studies, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Hematology, business.industry, General Medicine, Middle Aged, Prognosis, medicine.disease, body regions, Treatment Outcome, Chemotherapy, Adjuvant, Cytochrome P-450 CYP1B1, Female, Taxoids, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5595da0c67b8409b2e8a1b7b1b23d1Test
https://research.vumc.nl/en/publications/96018efa-575a-443a-b58a-d1486c35ebb8Test -
5
المؤلفون: O. W. M. Meijer, Geertjan van Tienhoven, Henk M.W. Verheul, Elisa Giovannetti, Anna M.E. Bruynzeel, Annette A. van Zweeden, Maarten A J M Jacobs, Johanna W. Wilmink, Geert Kazemier, Hans J. van der Vliet, Martijn R. Meijerink
المساهمون: Cancer Center Amsterdam, Oncology, Radiotherapy, Medical oncology, Radiology and nuclear medicine, Radiation Oncology, Medical oncology laboratory, Surgery, Gastroenterology and hepatology, CCA - Innovative therapy
المصدر: van Zweeden, A A, van der Vliet, H J, Wilmink, J W, Meijerink, M R, Meijer, O W M, Bruynzeel, A M E, van Tienhoven, G, Giovannetti, E, Kazemier, G, Jacobs, M A J M & Verheul, H M W 2015, ' Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer ', Clinical Cancer Research, vol. 21, no. 20, pp. 4569-4575 . https://doi.org/10.1158/1078-0432.CCR-14-3364Test
Clinical cancer research, 21(20), 4569-4575. American Association for Cancer Research Inc.
Clinical Cancer Research, 21(20), 4569-4575. American Association for Cancer Research Inc.مصطلحات موضوعية: Male, Oncology, Radiation-Sensitizing Agents, Cancer Research, medicine.medical_specialty, Maximum Tolerated Dose, Combination therapy, medicine.medical_treatment, Phases of clinical research, Antineoplastic Agents, Deoxycytidine, Disease-Free Survival, Internal medicine, medicine, Humans, Panitumumab, Progression-free survival, Aged, Performance status, business.industry, Antibodies, Monoclonal, Chemoradiotherapy, Middle Aged, Combined Modality Therapy, Gemcitabine, ErbB Receptors, Pancreatic Neoplasms, Radiation therapy, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8af044d3aa10a3aa41b4670af9233d5aTest
https://research.vumc.nl/en/publications/d841b4b3-1d46-4e67-931c-ea9631b374d0Test -
6
المؤلفون: Stefano Fogli, Elisa Giovannetti, F. de Braud, Romano Danesi, Giuseppe Curigliano, T. De Pas, M. Del Tacca
المساهمون: Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Fogli, S, Danesi, R, Braud, F D, Pas, T D, Curigliano, G, Giovannetti, E & Tacca, M D 2001, ' Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer ', Annals of Oncology, vol. 12, no. 11, pp. 1553-1559 . https://doi.org/10.1023/A:1013133415945Test
Annals of Oncology, 12(11), 1553-1559. Oxford University Pressمصطلحات موضوعية: Adult, Lung Neoplasms, Adolescent, Paclitaxel, medicine.medical_treatment, Cmax, Phases of clinical research, Pharmacology, Deoxycytidine, chemistry.chemical_compound, Pharmacokinetics, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Distribution (pharmacology), Infusions, Intravenous, Chromatography, High Pressure Liquid, Aged, Chemotherapy, Dose-Response Relationship, Drug, business.industry, Hematology, Middle Aged, Gemcitabine, Oncology, chemistry, Area Under Curve, Pharmacodynamics, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ad3167ac399acc3188842b8ae4949fTest
http://www.scopus.com/inward/record.url?scp=0035690123&partnerID=8YFLogxKTest -
7
المؤلفون: Ilaria Pastina, Sergio Ricci, Tristan M. Sissung, Romano Danesi, Douglas K. Price, William D. Figg, Cinzia Orlandini, Aldo Chioni, C. Cianci, Francesco Crea, Elisa Giovannetti
المساهمون: Medical oncology laboratory, CCA - Innovative therapy
المصدر: BMC Cancer, 10. BioMed Central
BMC Cancer
Pastina, I, Giovannetti, E, Chioni, A, Sissung, T M, Crea, F, Orlandini, C, Price, D K, Cianci, C, Figg, W D, Ricci, S & Danesi, R 2010, ' Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients ', BMC Cancer, vol. 10, pp. 511 . https://doi.org/10.1186/1471-2407-10-511Test
BMC Cancer, Vol 10, Iss 1, p 511 (2010)مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, Cancer Research, Genotype, medicine.medical_treatment, CYP1B1, Antineoplastic Agents, Pharmacology, lcsh:RC254-282, Prostate cancer, Surgical oncology, Internal medicine, medicine, Genetics, Humans, pharmacogenetics, docetaxel, prostate cancer, Aged, Aged, 80 and over, Chemotherapy, Predictive marker, Polymorphism, Genetic, business.industry, Prostatic Neoplasms, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Regimen, Treatment Outcome, Docetaxel, Drug Resistance, Neoplasm, Cytochrome P-450 CYP1B1, Multivariate Analysis, Taxoids, Aryl Hydrocarbon Hydroxylases, business, Pharmacogenetics, medicine.drug, Research Article
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d4b7502b090bab3a294e49896ddfdcTest
https://research.vumc.nl/en/publications/e3d52b71-e2c3-4422-b169-fb26d797e27bTest -
8
المؤلفون: Marco Del Chiaro, Jin Hyeok Hwang, Elisa Giovannetti, Sun-Whe Kim, Gyeong Hoon Kang, Joo Kyung Park, Godefridus J. Peters, Niccola Funel, Giuseppe Giaccone, Yong-Tae Kim, Leticia G. Leon, Johannes Voortman, Min A Kim, Seth M. Steinberg
المساهمون: Medical oncology, Medical oncology laboratory, CCA - Innovative therapy
المصدر: PLoS ONE, 5(5):e10630. Public Library of Science
PLoS ONE, Vol 5, Iss 5, p e10630 (2010)
Hwang, J H, Voortman, J, Giovannetti, E, Steinberg, S M, Leon, L G, Kim, Y T, Funel, N, Park, J K, Kim, M A, Kang, G H, Kim, S W, Del Chiaro, M, Peters, G J & Giaccone, G 2010, ' Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer ', PLoS ONE, vol. 5, no. 5, e10630, pp. e10630 . https://doi.org/10.1371/journal.pone.0010630Test
PLoS ONEمصطلحات موضوعية: Male, Oncology, Pathology, medicine.medical_treatment, Gastroenterology and Hepatology/Pancreas, lcsh:Medicine, Cohort Studies, Recurrence, Medicine, lcsh:Science, Oligonucleotide Array Sequence Analysis, Multidisciplinary, Hazard ratio, Middle Aged, Gene Expression Regulation, Neoplastic, Treatment Outcome, Italy, Chemotherapy, Adjuvant, Fluorouracil, Biomarker (medicine), Female, Adjuvant, Research Article, Carcinoma, Pancreatic Ductal, medicine.drug, medicine.medical_specialty, Gastroenterology and Hepatology/Gastrointestinal Cancers, Oncology/Gastrointestinal Cancers, Disease-Free Survival, Pancreatic cancer, Internal medicine, Biomarkers, Tumor, Adjuvant therapy, Carcinoma, Humans, Molecular Biology, Genetics and Genomics/Cancer Genetics, Aged, Cell Proliferation, Proportional Hazards Models, Korea, business.industry, Proportional hazards model, lcsh:R, Reproducibility of Results, medicine.disease, Pancreatic Neoplasms, MicroRNAs, Drug Resistance, Neoplasm, Multivariate Analysis, lcsh:Q, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82084ac8872d14c0371f6226ddffd380Test
https://research.vumc.nl/en/publications/395c4790-f76e-41bb-9005-55a897b80fc6Test